Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer

PURPOSE: Combination of biological therapy and chemotherapy improves the survival of patients with metastatic colorectal cancer (mCRC). However, the optimal biological therapy sequence remains unclear. In this retrospective study, we evaluated the clinical outcomes of patients with mCRC treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Hung‐Chih, Liu, Yu‐Chun, Wang, Chuang‐Wei, Chou, Wen-Chi, Hsu, Yu-Jen, Chiang, Jy-Ming, Lin, Yung-Chang, Yang, Tsai-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601597/
https://www.ncbi.nlm.nih.gov/pubmed/31090176
http://dx.doi.org/10.1002/cam4.2235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601597/
https://www.ncbi.nlm.nih.gov/pubmed/31090176
http://dx.doi.org/10.1002/cam4.2235

Ejemplares similares